SANUWAVE Health (SANUWAVE Health) Cash Flow from Financing : $5.21 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is SANUWAVE Health Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, SANUWAVE Health paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $1.78 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.07 Mil on other financial activities. In all, SANUWAVE Health earned $1.86 Mil on financial activities for the three months ended in Dec. 2023.

SANUWAVE Health Cash Flow from Financing Historical Data

The historical data trend for SANUWAVE Health's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SANUWAVE Health Cash Flow from Financing Chart

SANUWAVE Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

7.86

33.45

5.12

17.38

5.21

SANUWAVE Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial															4.72	-0.65	2.08	1.93	1.86

SANUWAVE Health Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

SANUWAVE Health's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	5.85	+	0	+	0	+	-0.639
=	5.21

SANUWAVE Health's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	1.784	+	0	+	0	+	0.071
=	1.86

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.21 Mil.

SANUWAVE Health (OTCPK:SNWV) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

SANUWAVE Health's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

SANUWAVE Health's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

SANUWAVE Health's net issuance of debt for the three months ended in Dec. 2023 was $1.78 Mil. SANUWAVE Health received $1.78 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

SANUWAVE Health's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. SANUWAVE Health paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

SANUWAVE Health's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. SANUWAVE Health received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

SANUWAVE Health's other financing for the three months ended in Dec. 2023 was $0.07 Mil. SANUWAVE Health received $0.07 Mil on other financial activities.

SANUWAVE Health Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of SANUWAVE Health's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

SANUWAVE Health (SANUWAVE Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SANUWAVE Health Inc (OTCPK:SNWV) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

11495 Valley View Road, Eden Prairie, MN, USA, 30024

Website

https://www.sanuwave.com

SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.

Executives

Andrew Walko	officer: President	11495 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Manchester Management Pr, Llc	director, other: Director by Deputization	3 WEST HILL PLACE, BOSTON MA 02114
James E Besser	director, other: Director by Deputization	3 WEST HILL PLACE, BOSTON MA 02114
Manchester Explorer, L.p.	director, other: Director by Deputization	MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
Morgan C. Frank	director	2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc	director, other: Director by Deputization	3 WEST HILL PLACE, BOSTON MA 02110
Thomas Edmunds Price	director	3360 MARTIN FARM ROAD, SUITE 100, SUWANEE GA 30024
Shri P. Parikh	officer: President	3360 MARTIN FARM ROAD, SUITE 100, SUWANEE GA 30024
Richardson Kevin A Ii	10 percent owner	200 HIGH STREET, SUITE 700, BOSTON MA 02110
Anthony Michael Stolarski	director	99 W. ARLINGTON HEIGHTS, NORTH AUGUSTA SC 29841
Sanuwave Health, Inc.	director	3360 MARTIN FARM RD, SUITE 100, SUWANEE GA 30024
Lisa E Sundstrom	officer: Interim CFO	11475 GREAT OAKS WAY, STE 150, ALPHARETTA GA 30022
Joseph Chiarelli	director, officer: Chief Executive Officer	510 FAIRVIEW AVENUE, WYCKOFF NJ 07481
Barry J. Jenkins	officer: Chief Financial Officer	11680 GREAT OAKS WAY, SUITE 350, ALPHARETTA GA 30022
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105